The adolescent onset anorexia nervosa study (ANABEL): Design and baseline results. Issue 3 (21st August 2018)

• Record Type: Journal Article
• Authors: Graell, Montserrat; de Andrés, Patricia; Sepúlveda, Ana Rosa; Moreno, Alba; Villaseñor, Ángel; Faya, Mar; Martínez‐Cantarero, Carmen; Gómez‐Martínez, Sonia; Marcos, Ascensión; Morandé, Gonzalo; Nova, Esther
• Is Part Of: International journal of methods in psychiatric research. Volume 27:Issue 3(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-08-21
• Subjects: adolescence -- adolescents -- eating disorders -- longitudinal design -- risk factors; Psychiatry -- Research -- Methodology -- Periodicals; Psychiatry -- Periodicals; 616.890072
• DOI: 10.1002/mpr.1739
• Languages: English
• ISSNs: 1049-8931

Abstract

Abstract: The anorexia nervosa adolescent longitudinal biomarker assessment study (ANABEL) is a 2‐year longitudinal study. Objective: Evaluate several clinical, biochemical, immunological, psychological, and family variables and their interactions in adolescent onset eating disorders (EDs) patients and their 2‐year clinical and biological outcome. This article illustrates the framework and the methodology behind the research questions, as well as describing general features of the sample. Methods: A longitudinal study of 114 adolescents with EDs seeking treatment was performed. Only adolescents were selected during 4 years (2009–2013). The variables were collected at different times: baseline, 6, 12, 18, and 24 months of the start of treatment. Diagnoses were completed through the semi‐structured Kiddie‐Schedule for Affective Disorders and Schizophrenia interview. Results: At baseline, the mean age was 15.11 ( SD = 1.36). The mean ED duration was 10 months ( SD = 5.75). The mean body mass index was 16.1 ( SD = 1.8). The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis at baseline for restrictive anorexia nervosa was 69.6%, 17.4% for purgative anorexia nervosa, and 24.3% for other specified feeding disorder. At 12 months, 19.4% were in partial remission, whereas at 24 months, 13.8% had fully recovered and 29.2% had partially recovered. Conclusions: There was an acceptable physical and psychopathological improvement during the first year of treatment, with recovery being more evident during the first 6 months.